Dr Reddys unveils Gemcitabine for Injection in US

28 Jul 2011 Evaluate

Dr Reddy’s Laboratories has launched Gemcitabine for Injection (200 mg/vial and 1 g/vial), a bioequivalent generic version of Gemzar in the US market, following the approval by the United States Food & Drug Administration (USFDA) of Dr Reddy’s Abbreviated New Drug Application (ANDA) for Gemcitabine for injection.

The Gemzar brand had US sales of about $634 million for the most recent twelve months ending May 31, 2011. The company’s Gemcitabine for Injection 200mg/vial and 1 g/vial strengths are available in single-use vials.

Dr Reddys, a global pharmaceutical company, has a global presence in more than 100 countries, with subsidiaries in the US, UK, Russia, Germany and Brazil; joint ventures in China, South Africa and Australia; representative offices in 16 countries and third-party distribution set ups in 21 countries.

Dr. Reddys Lab Share Price

1275.05 -1.95 (-0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×